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Airway hyperresponsiveness (AHR) and airway inflammation are key pathophysiological
features of asthma. Bronchial provocation tests (BPTs) are objective tests for AHR that are
clinically useful to aid in the diagnosis of asthma in both adults and children. BPTs can be
either “direct” or “indirect,” referring to the mechanism by which a stimulus mediates bron-
choconstriction. Direct BPTs refer to the administration of pharmacological agonist (e.g.,
methacholine or histamine) that act on specific receptors on the airway smooth muscle.
Airway inflammation and/or airway remodeling may be key determinants of the response to
direct stimuli. Indirect BPTs are those in which the stimulus causes the release of mediators
of bronchoconstriction from inflammatory cells (e.g., exercise, allergen, mannitol). Airway
sensitivity to indirect stimuli is dependent upon the presence of inflammation (e.g., mast
cells, eosinophils), which responds to treatment with inhaled corticosteroids (ICS). Thus,
there is a stronger relationship between indices of steroid-sensitive inflammation (e.g.,
sputum eosinophils, fraction of exhaled nitric oxide) and airway sensitivity to indirect com-
pared to direct stimuli. Regular treatment with ICS does not result in the complete inhibition
of responsiveness to direct stimuli. AHR to indirect stimuli identifies individuals that are
highly likely to have a clinical improvement with ICS therapy in association with an inhibi-
tion of airway sensitivity following weeks to months of treatment with ICS.To comprehend
the clinical utility of direct or indirect stimuli in either diagnosis of asthma or monitoring of
therapeutic intervention requires an understanding of the underlying pathophysiology of
AHR and mechanisms of action of both stimuli.
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INTRODUCTION
Airway hyperresponsiveness (AHR) is one of the hallmark fea-
tures of asthma. Bronchial provocation tests (BPTs) are used to
assess the presence of AHR to assist in making a clinical diagnosis
of asthma in individuals with symptoms and signs that suggest
asthma. Asthma is defined as a chronic inflammatory disorder of
the airways in which many cells and cellular elements play a role
[Global Initiative for Asthma (GINA), 2007]. The chronic inflam-
mation is associated with AHR that leads to recurrent episodes
of wheezing, chest tightness, and coughing [Global Initiative for
Asthma (GINA), 2007]. It is also understood that the pathophysi-
ology of asthma can lead to a variety of more permanent changes in
the airway, which is commonly known as “remodeling” (Holgate
et al., 2010). Asthma symptoms are the most clinically accessi-
ble marker of disease activity. However, symptoms often do not
reflect the degree of airway inflammation and AHR, the two key
features attenuated by the mainstay therapy for asthma, inhaled
corticosteroids (ICS; Sont et al., 1996).
Bronchial provocation tests are useful in a clinical setting if
spirometry is normal and a reversibility test using a standard
dose of β2-agonist does not demonstrate significant reversibil-
ity or bronchodilatation. They may also be useful if a past history
of asthma has not been substantiated by objective measures of
lung function documenting reversible airflow obstruction, as well
as in the evaluation of atypical symptoms such as chronic cough
(Irwin, 2006). BPTs may be particularly relevant to perform prior
to beginning an occupation or sporting activity that may exacer-
bate or cause an attack of asthma, and to diagnose and monitor
work-related asthma (Tarlo et al., 2008).
Bronchial provocation tests have played a significant role in
research to understand mechanisms of AHR, mechanisms of dys-
pnea and cough in asthma (Lougheed et al., 1993, 1995; Turcotte
and Lougheed, 2011) and to investigate the efficacy of pharma-
cotherapy used in the prevention of AHR and treatment of asthma
(O’Byrne et al., 2009a). BPTs have been used to investigate AHR
following both short- and long-term treatment with regular ICS
in order to justify changes in ICS dose in a clinical setting (Sont
et al., 1999; Lipworth et al., 2012; Turton et al., 2012).
This review will discuss the BPTs available for clinical use and
outline the different mechanisms by which each test identifies
AHR. We will review the effects of pharmacotherapy used in the
treatment of asthma that inhibits AHR, for the purposes of doc-
umenting efficacy of treatment in research or in an individual in
the clinic. Where possible we will demonstrate the differences and
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similarities between adults and children however the majority of
research cited pertains to adult asthma.
DIRECT BRONCHIAL PROVOCATION TESTS
Direct BPTs refer to the use of single agonist such as metha-
choline or histamine that act directly on receptors on the airway
smooth muscle (ASM) causing contraction. The most widely used
is methacholine which acts on muscarinic (M3) receptors, while
histamine acts on H1 receptors (Figure 1). These agents are admin-
istered using standardized protocols either through tidal breathing
using a nebulizer or deep inhalations using a dosimeter method
(Ryan et al., 1981; Crapo et al., 2000), while documenting the
response to each dose. A 20% fall in the forced expiratory volume
in 1 s (FEV1) is considered as a positive test and the provocative
concentration (PC20) or dose (PD20) of agonist to cause this fall is
calculated by interpolation from the dose-response curve. Metha-
choline has regulatory approval by the United States Food and
Drug Administration (US FDA) and Health Canada, however no
such approvals have been obtained for histamine.
Individuals with asthma often are more sensitive and reactive
to these agents compared with those who do not have asthma.
It is now better understood that AHR to direct stimuli can be
considered to have two components of the response that are
considered “fixed” and “variable” (Cockcroft, 2010). The variable
component is considered to change rapidly, for example following
inhalation of an allergen which can increase AHR by acutely up-
regulating airway inflammation. Alternatively, regular use of ICS,
which are potent anti-inflammatory agents, is known to attenu-
ate, though not completely inhibit AHR to direct agents (Brannan,
2010). Thus, the variable component is considered to reflect the
inflammatory aspect of AHR to direct agents. Conversely, the fixed
component is thought to reflect more chronic persistent (possibly
permanent) structural and functional changes in the airway that
may or may not be due to airway inflammation, such as airway
remodeling (Cockcroft, 2010). AHR can persist despite high-dose
ICS over long treatment periods (Sont et al., 1996; Brannan, 2010).
The different contribution each component has on the airway sen-
sitivity to direct stimuli cannot be determined from a single test
as little research has been performed in an attempt to elucidate
the components of the response. For example, it is possible that
some individuals who do not have asthma may respond to direct
agents (Hewitt, 2008) in the absence of an inflammatory compo-
nent at the time of testing, potentially indicating the presence of a
remodeling process.
Direct tests are considered to have a high diagnostic sensitiv-
ity for the presence of current asthma (Cockcroft, 2010). That is,
most individuals with a clinical diagnosis of asthma will respond
to these stimuli. However, several recent studies suggest that in
some patient groups the diagnostic sensitivity of direct stimuli may
not be as high as initially reported. The diagnostic sensitivity of
FIGURE 1 | A schematic demonstrating the mechanism of action of common bronchoconstricting stimuli delivered as standardized bronchial
provocation tests in the research and clinical setting.
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methacholine in asthmatics taking regular ICS has been reported
to be 77%, while the sensitivity was significantly reduced in Cau-
casians (69%) compared to African Americans (95%; Sumino
et al., 2012). Further, there was a significant reduction in sensitivity
when comparing those who were non-atopic (52%) versus atopic
(82%). A similar decrease in diagnostic sensitivity of methacholine
to identify asthma has been observed in non-atopic versus atopic
children in cohort studies (Liem et al., 2008). Further, there is
increasing evidence that AHR to direct stimuli has a low sensitivity
to identify the presence of exercise-induced bronchoconstriction
(EIB) in adults and children (Haby et al., 1994; Holzer et al.,
2002; Anderson et al., 2009; Sue-Chu et al., 2010; Holley et al.,
2012). That is, individuals with significant EIB may have no air-
way sensitivity to direct stimuli. However protocols that require
the administration of methacholine using a deep inspiration have
demonstrated decreased sensitivity to identify AHR compared to
those using a tidal breathing method (Todd et al., 2004; Cockcroft
and Nair, 2012). It is well established that a deep inhalation can
have a protective effect on AHR in non-asthmatics (Kapsali et al.,
2000). It has been hypothesized that the attenuation of the bron-
chodilator and/or bronchoprotective effect of a deep inspiration
contribute to the severity of the clinical manifestations of asthma
(Scichilone et al., 2007). However evidence for this bronchopro-
tection has been observed in mild asthmatics and it may be lost in
the presence of more active airway inflammation and poorer lung
function (Allen et al., 2008; Pyrgos et al., 2011).
Epidemiologic studies in adults and children have established
that direct BPTs can have a low specificity for asthma (Woolcock
and Peat, 1989). For example, it is well established that individu-
als with other lung disease, atopy, allergic rhinitis, and individuals
who smoke may demonstrate AHR to direct stimuli (Ramsdale
et al., 1985; Tashkin et al., 1992; Britton et al., 1994; Sunyer et al.,
1997; Hewitt, 2008). It is not clear why these subjects respond how-
ever, it is possible that either one of or both the variable and fixed
components may be present. There is evidence that reduced air-
way caliber may be a predictor of the response (Britton et al., 1994;
Litonjua et al., 1999; Parker and McCool, 2002; Parker et al., 2003).
Further, larger airways may provide some protective effect on the
airway response in individuals with asthma. In a large population
of physician-diagnosed asthmatics, it was observed that 27% had a
negative methacholine challenge test and these subjects were more
likely to have better lung function than those who had a positive
test (McGrath and Fahy, 2011). Other evidence to support air-
way size being a determinant of AHR to direct stimuli arises from
studies demonstrating that the severity of AHR decreased with age
from childhood to adolescence (Sears et al., 2003). Imaging studies
in humans have not provided clear evidence between a relation-
ship with airway sensitivity to methacholine and lung function
(Boulet et al., 1989).
There can be a high prevalence of AHR to direct stimuli in
athletes, in particularly winter athletes who do not demonstrate
significant EIB (Sue-Chu et al., 2010). This observation has sup-
ported the concept that AHR to these agents in these subjects may
identify a type of airway damage or remodeling due to the effects
of high intensity exercise (Kippelen et al., 2012).
In well established asthmatic populations, there is evidence
of a relationship between the airway sensitivity to direct stimuli
and clinically accessible markers of inflammation such as spu-
tum eosinophils, as well as non-specific markers of inflammation
such as the fraction of exhaled nitric oxide (FeNO; Jatakanon
et al., 1998). However, others have not shown such relationships
in patients with well established allergic asthma (Crimi et al.,
1998). These differences may be accounted for by the presence
of remodeling and its influence on the airway sensitivity to these
agents.
INDIRECT BRONCHIAL PROVOCATION TESTS
Indirect BPTs refer to stimuli such as dry air hyperpnea or stim-
uli administered via an aerosol such as allergens, osmotic agents
(e.g., mannitol or hypertonic saline), or adenosine monophos-
phate (AMP), that cause the release of a variety of mediators of
bronchoconstriction from inflammatory cells (Figure 1). Media-
tors such as histamine, prostaglandins, and leukotrienes then act
on specific receptors on the ASM to cause contraction and airway
narrowing. The mast cell is thought to play a dominant role in con-
tributing to the source of mediators (Anderson, 2010). Tryptase
containing mast cells predominate in lung tissue (Andersson et al.,
2009), however it is their location in the airway epithelium and the
ASM that may be of significant importance in AHR (Brightling
et al., 2002; Dougherty et al., 2010). There may be some involve-
ment from airway sensory nerves, in particular to dry air hyper-
pnea and the osmotic stimuli as a result of airway cooling and
changes in osmolarity (Anderson et al., 1996).
Inhaled allergens cause mast cell degranulation by crosslink-
ing with Immunoglobulin E via the FcεRI receptor on the surface
of the mast cell. Both dry air hyperpnea and osmotic stimuli are
considered to raise the osmolarity of the airway surface, leading to
movement of water into the airway lumen and a resultant increase
in airway tissue osmolarity. It has been demonstrated in vitro that
the mast cell is sensitive to osmotic change, with the ability to
release histamine, prostaglandins, and leukotrienes, importantly
in the presence of IgE (Eggleston et al., 1984, 1990; Gulliksson
et al., 2006). AMP acts directly on mast cells to cause degranula-
tion and release of mediators via action on the A2b receptor (Van
Schoor et al., 2000).
Indirect test protocols include exercise testing either via a
treadmill or cycle ergometer, eucapnic voluntary hyperventilation
(EVH), nebulized hypertonic saline, inhaled dry powder mannitol,
or AMP, all of which have well established and standardized pro-
tocols (Van Schoor et al., 2000; Anderson and Brannan, 2003).
Inhaled mannitol has been approved by regulatory authorities
in 26 countries including the US FDA as a standardized test kit
(www.mannitoltest.info). Allergen inhalation is primarily used in
research as it can cause a late airway response approximately 6–8 h
following the early bronchoconstriction (O’Byrne et al., 2009a).
However, the clinical use of specific allergen inhalation tests is
limited to specialized tertiary care centers, for example to evaluate
work-related asthma (Tarlo et al., 2008).
Exercise and EVH are given as a bolus dose of ventilation and
changes in airway caliber are measured by the forced expiratory
volume in 1 s (FEV1) over 15–20 min following the stimulus and
comparing this to the baseline FEV1 value (Anderson and Bran-
nan, 2003). A positive response is documented as a 10–15% fall in
FEV1 and the severity of the response is determined by the degree
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of the fall in FEV1. In known asthmatics, large falls in FEV1 can be
observed when using these tests so for clinical use they are often
confined to individuals who are suspected of having EIB with nor-
mal lung function (Brannan et al., 1998; Porsbjerg and Brannan,
2010). These tests differ from the dose-response challenges such
as the osmotic stimuli or AMP where, like the direct challenges,
the stimulus is given in increasing doses and changes in FEV1 are
documented until a 15% (mannitol, hypertonic saline) or 20%
(AMP) fall or no target response is obtained by the maximum
dose. The airway sensitivity is defined as the provoking dose of the
stimulus to cause a 15 or 20% fall in FEV1 which is calculated by
linear interpolation of the dose-response curve (PD15 or PD20).
Some studies have investigated the use of a 10% fall in FEV1 to
mannitol (PD10) for both monitoring ICS and identifying EIB in
elite athletes (Holzer et al., 2003; Lipworth et al., 2012). These tests
have a good safety profile as large falls in FEV1 can be avoided
(Joos et al., 2003; Brannan et al., 2005).
There have been few studies firmly establishing the use of these
challenge tests to investigate conditions that may mimic asthma
or EIB, such as laryngeal obstruction (e.g., vocal chord dysfunc-
tion), inspiratory stridor, or other conditions such as hyperven-
tilation syndrome in either adults or children (McFadden and
Zawadski, 1996; Rundell and Spiering, 2003; Weinberger and Abu-
Hasan, 2007). The presence of symptoms suggestive of asthma, in
the absence of AHR to an indirect test certainly warrants fur-
ther investigation. Additional investigations which may be helpful
include examination of the shape of the flow-volume loop, direct
laryngoscopy, and the measurement of end-tidal CO2 on exercise.
The mechanism by which indirect stimuli identify AHR is simi-
lar to most clinically relevant stimuli that cause AHR in individuals
with asthma. These stimuli require the presence of inflammation
in the airway. Thus, a response to these stimuli identifies the inter-
action of the two key features of asthma, inflammation, and AHR.
It has been well established that the airway sensitivity to indirect
agents is related to the presence and degree of airway inflam-
mation. The severity of the airway response to hypertonic saline
is related to the presence of mast cells in brush biopsy and in
sputum in children (Gibson et al., 1998, 2000). Those with EIB
demonstrate significantly greater numbers of mast cells in the air-
way epithelium compared to those without EIB (Hallstrand et al.,
2011). There are significantly more eosinophils in the sputum of
asthmatics with EIB compared to those without EIB and there is
a relationship with the presence of eosinophils in sputum and the
severity of EIB (Yoshikawa et al., 1998; Kivity et al., 2000; Duong
et al., 2008) and the airway sensitivity to mannitol (Porsbjerg et al.,
2008). Further, studies comparing direct and indirect BPTs have
demonstrated that the airway sensitivity to both AMP and man-
nitol have a significant relationship to the degree of eosinophils
in induced sputum when compared to methacholine in the same
asthmatic subjects (Van Den Berge et al., 2001; Porsbjerg et al.,
2008; Figure 2). There are also studies identifying significant
relationships with FeNO, a non-specific marker of airway inflam-
mation with the airway sensitivity to exercise and mannitol (Scollo
et al., 2000; Porsbjerg et al., 2008; Figure 3). However, a propor-
tion of asthmatics who have airway sensitivity to mannitol have
FeNO values well within the normal range (i.e., <20ppb; Porsb-
jerg et al., 2008; Cowan et al., 2010). Further, both eosinophilic
and non-eosinophilic phenotypes have been observed in asthmat-
ics responsive to both hypertonic saline and mannitol (Simpson
et al., 2006; Porsbjerg et al., 2009). Non-eosinophilic phenotypes
FIGURE 2 |The relationship between the airway sensitivity to inhaled
methacholine and mannitol compared to the percentage (%) of
eosinophils in sputum in a selected group of steroid naïve asthmatic
subjects. Airway hyperresponsiveness (AHR) to mannitol is defined as a 15%
reduction in the forced expiratory volume in 1 s (FEV1) to a cumulative dose of
less than 635 mg (PD15); for methacholine as a 20% reduction in FEV1 to less
than eight micromoles (PD20). The relationship of % eosinophils with those
who had a positive AHR (closed circles) was significant for mannitol
(rp =−0.52, p<0.05) compared to methacholine (rp =−0.28, p=ns). Those
who had no AHR to either mannitol or methacholine (open squares) in this
group of subjects had significantly less sputum eosinophils (adapted from
Porsbjerg et al., 2008).
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FIGURE 3 |The relationship between the airway sensitivity to
inhaled methacholine and mannitol compared to the fraction of
exhaled nitric oxide (FeNO) in parts per billion (ppb) in a selected
group of steroid naïve asthmatic subjects. Airway
hyperresponsiveness (AHR) to mannitol is defined as a 15% reduction in
the forced expiratory volume in 1 s (FEV1) to a cumulative dose of less
than 635 mg (PD15); for methacholine as a 20% reduction in FEV1 to less
than eight micromoles (PD20). The relationship of FeNO with those who
had a positive AHR (closed circles) was more significant for mannitol
(rp =−0.63, p<0.001) compared to methacholine (rp =−0.43, p<0.05).
There were a proportion of subjects with AHR that had normal FeNO
values (adapted from Porsbjerg et al., 2008).
may include those with neutrophils or those who have neither
neutrophils or eosinophils in sputum (also known as paucigranu-
locytic). These studies have shown milder AHR to indirect stimuli
in subjects with a non-eosinophilic phenotype. This data suggests
that there are subjects with AHR which involves active mast cells
in the absence of significant eosinophilia or raised FeNO levels.
There is increasing evidence that indirect stimuli cause mast
cell mediator release in vivo. Studies attempting to measure medi-
ators of bronchoconstriction have identified increases in arterial
plasma histamine levels measured at the time of maximal air-
way narrowing to exercise (Anderson et al., 1981). Leukotriene
E4 (LTE4) or the metabolite of prostaglandin D2, 9α,11β-PGF2,
a marker of mast cell release, are measured in urine (Reiss et al.,
1997; O’Sullivan et al., 1998b; Mickleborough et al., 2003) and spu-
tum (Hallstrand et al., 2005) following EIB. Similar observations
identifying increases in urinary 9α, 11β-PGF2 have been made
with mannitol, hypertonic saline (in children), and EVH (Bran-
nan et al., 2003; Mai et al., 2005; Kippelen et al., 2010) as well as
allergen challenge (O’Sullivan et al., 1998a), further supporting the
role of the mast cell in the airway response to these stimuli. Some
of these studies have also found an increase in both 9α,11β-PGF2
and LTE4 in the urine of non-asthmatics who have no BHR with
indirect stimuli (Brannan et al., 2003; Mickleborough et al., 2003;
Mai et al., 2005). Thus, the sensitivity of the ASM is an important
component of the response to indirect stimuli.
The degree of AHR to direct stimuli is often associated with the
airway sensitivity to indirect stimuli in individuals with established
asthma (Anderson et al., 1997; Koh and Choi, 2002). However, air-
way responses to indirect stimuli can occur in the absence of AHR
to either methacholine or histamine in adults and children (Haby
et al., 1994; Holzer et al., 2003; Anderson et al., 2009; Holley et al.,
2012). The explanation for the lack of relationship presumably lies
in the differences in mechanisms of action of both direct and indi-
rect stimuli. A variety of endogenous mediators are involved in the
airway response to indirect stimuli. These include leukotrienes and
prostaglandins which are both known to be more potent at caus-
ing airway narrowing than methacholine or histamine (O’Hickey
et al., 1988). Thus EIB in the absence of an airway response to direct
stimuli may be a result of a heightened sensitivity to endogenous
mediators (Anderson, 2010).
ASSESSING EFFICACY OF ASTHMA PHARMACOTHERAPY
USING AHR
DIRECT AHR
Airway hyperresponsiveness to direct stimuli is used as a research
tool in drug development to assess the efficacy of new and existing
therapies used in the acute and long-term treatment of asthma.
The ability of these therapies to inhibit AHR has in turn pro-
vided some explanation as to the mechanisms of direct AHR.
Acutely, β2-agonists are powerful inhibitors of ASM contractil-
ity capable of decreasing AHR to direct stimuli (Page and Spina,
2006). β2-agonists protect against ASM contraction from direct
stimuli by non-specific functional antagonism via β2 receptor-
induced ASM relaxation. The methacholine challenge is a recog-
nized methodology for assessing efficacy and duration of action of
bronchoprotection and the pharmacoequivalence of β2-agonists
(Parameswaran et al., 1999; O’Byrne et al., 2009b). While these
drugs are the most effective pharmacotherapy to inhibit the air-
way response to direct stimuli, the protection is not complete in
all subjects (Page and Spina, 2006). Asthmatics who regularly use
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β2-agonists can demonstrate increased airway sensitivity to direct
stimuli, a decreased bronchoprotection, as well as a slower recov-
ery to these challenge tests following a standard dose of rescue
β2-agonist (Cheung et al., 1992; Kalra et al., 1996; Haney and Han-
cox, 2005). This may need to be considered when investigating the
efficacy of a β2-agonist.
The acute use of a leukotriene antagonist and the mast cell
stabilizing drugs demonstrate minimal to no effect on AHR to
direct stimuli (Patel, 1984; Boner et al., 1987; Crimi et al., 1987;
Davis and Cockcroft, 2005). This suggests there are limitations
in using direct stimuli to investigate the bronchoprotective effect
of antagonists that target other receptors or agents that stabi-
lize the mast cell. However, long-term use of cromoglycate and
montelukast has shown some small effect on attenuating the sen-
sitivity to direct stimuli (Bel et al., 1990; Groot et al., 1992; Hakim
et al., 2007). The short acting anti-cholinergic ipratropium bro-
mide has a potent inhibitory effect on AHR to methacholine that
is lost over 12 h (Crimi et al., 1992; Illamperuma et al., 2009).
However the longer acting anti-cholinergic tiotropium demon-
strates more potent inhibition and longer duration of protection
against methacholine-induced bronchoconstriction (O’Connor
et al., 1996).
Regular use of ICS can attenuate direct AHR (Juniper et al.,
1990; Reddel et al., 2000). AHR to direct BPTs have been used
to guide the dose of ICS to monitor asthma compared to asthma
guidelines in both adults and children (Sont et al., 1999; Nuijsink
et al., 2007). However, AHR to direct stimuli may remain in many
individuals with asthma on long-term ICS therapy over months
to years of treatment (Figure 4). The short-term improvements in
direct AHR as a result of ICS therapy may be related to reductions
in airway inflammation (du Toit et al., 1997), while more long-
term improvement in AHR may be indicative of a reduction in
airway remodeling (Sont et al., 1999).
The repeated evaluation of direct AHR to aid in clinical mon-
itoring of the efficacy of ICS was made using a treatment strat-
egy aimed at reducing AHR to methacholine (AHR strategy)
compared to a parallel group who were treated based on rec-
ommendations in the existing guidelines (reference strategy) in
asthmatic adults (Sont et al., 1999). Following 2 years of ICS ther-
apy, there was a 1.8-fold lower incidence of mild exacerbations and
a significantly sustained improvement in pre-bronchodilator FEV1
using the AHR strategy. This was associated with improvements
in the reticular layer thickness beneath the epithelium, suggesting
improvements in airway remodeling. Interestingly, AHR docu-
mented as a mean PC20 to methacholine of 0.47 mg/mL before
treatment, was not attenuated using the AHR strategy (increase
in PC20 1.1 doubling concentrations, not statistically significant).
This confirmed previous studies showing that long-term treat-
ment with ICS does not necessarily reduce AHR to methacholine
to anywhere near the normal range (e.g.,>16 mg/mL) or abolish
AHR to direct stimuli (Figure 4; du Toit et al., 1997; Lim et al.,
1999). A similar study in asthmatic children over 2 years found
no increase in the number of symptom-free days using the AHR
strategy (Nuijsink et al., 2007). They did however observe a bet-
ter pre-bronchodilator FEV1 in a sub-group of allergic asthmatic
children. To afford these clinical benefits, both studies observed
the use of higher dose of ICS using the AHR strategy. While these
results are inconclusive about monitoring ICS with direct stimuli
these studies demonstrate it is difficult to identify optimal therapy
when the AHR to these stimuli remains.
INDIRECT AHR
Pharmacotherapy for the treatment of asthma has also revealed
much about the mechanism of indirect AHR. Acute use of
β2-agonists demonstrates the most potent protective effect on
indirect stimuli, likely due to a combination of non-specific
FIGURE 4 | A summary of the improvement in AHR following
treatment with inhaled corticosteroids (ICS) expressed as a
provoking dose (PD20) or provoking concentration (PC20) to cause a
20% fall in FEV1 from six studies using either histamine or
methacholine (duToit et al., 1997; Lim et al., 1999; Sont et al., 1999;
Reddel et al., 2000; Foresi et al., 2005; Jenkins et al., 2005). Significant
AHR to direct stimuli remains in the presence of high doses of ICS over
short- and long-term treatment periods.
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functional antagonism of the released mediators causing bron-
choconstriction, as well as via β2-receptor-mediated mast cell
stabilization (Anderson et al., 2006). However, regular use of β2-
agonists, like their effects on direct stimuli, may increase the airway
sensitivity to indirect stimuli, decrease the ability of β2-agonists
when used acutely to bronchoprotect, and have decreased efficacy
when being used to recover from indirect bronchoconstriction
(Hancox et al., 2002; Anderson et al., 2006; Haney and Han-
cox, 2006). Acute use of drugs such as sodium cromoglycate and
nedocromil sodium inhibits AHR to indirect stimuli due to their
mast cell stabilizing properties (Brannan et al., 2000, 2006; Kelly
et al., 2001; Kippelen et al., 2010). The expected increases in the uri-
nary excretion of the mast cell marker 9α,11β-PGF2 following both
mannitol and EVH are attenuated in the presence of cromoglycate
and a β2-agonist (Brannan et al., 2006; Kippelen et al., 2010). The
mast cell stabilizing drugs may also play a role by inhibiting air-
way sensory nerves or acting on the airway epithelium (Anderson
et al., 1996), however they have little effect on suppressing cough
to osmotic stimuli in relation to their powerful inhibitory effect on
indirect AHR (Koskela et al., 2005). Leukotriene antagonists such
as montelukast are powerful at inhibiting the action of leukotrienes
on the ASM, causing a rapid recovery from AHR to indirect stim-
uli (Reiss et al., 1997; Brannan et al., 2001). Histamine antagonists
have a weak though noticeable effect on reducing airway sensitiv-
ity to some indirect stimuli (Brannan et al., 2001; Anderson and
Brannan, 2002; Dahlen et al., 2002). Research using these drugs has
revealed the importance of the mast cell and pre-formed histamine
on the initial airway response, while leukotrienes are subsequently
released“de novo”to sustain bronchoconstriction to indirect stim-
uli. Anti-cholinergic drugs do demonstrate inhibition on indirect
stimuli such as exercise and hypertonic saline (Boulet et al., 1989).
However the protection is incomplete and not uniform, demon-
strating wide interindividual variability. However this does not
diminish the role of the neural response to indirect stimuli, as it is
well known that these stimuli can activate sensory nerves which are
likely responsible for cough, even in the absence of bronchocon-
striction (Koskela et al., 2004, 2005). There is some evidence that
interindividual variability for the bronchoprotection to exercise
is related to the degree of cardiac vagal activity (Knopfli et al.,
2005). However there is little data assessing the role of the newer
more potent anti-cholinergics on BHR to indirect stimuli and fur-
ther research is warranted to investigate the role of airway sensory
nerves.
The regular use of ICS is well known to attenuate but also abol-
ish the airway sensitivity to indirect stimuli (Koh et al., 2007).
Abolishing responses to indirect stimuli using ICS may provide
an objective marker for asthma control (Brannan, 2010). Such an
endpoint may also indicate an opportunity for down-titration of
ICS dose (Leuppi et al., 2001; Brannan et al., 2012). It is well estab-
lished that both mast cells and eosinophils, known to be sensitive
to ICS, play an important role in the airway response. Both cells
are known to decrease in number in the presence of regular ICS
therapy (Djukanovic et al., 1992). Thus, an airway response to an
indirect stimuli is thought to identify an individual who is likely
to have AHR that will benefit from ICS. Thus they have poten-
tial for monitoring the efficacy of ICS in both adults and children
FIGURE 5 |The provoking dose of mannitol to cause a 15% fall in
FEV1 (PD15) following short-term (6–9weeks) and long-term
(6months) treatment with inhaled corticosteroids (ICS; Brannan
et al., 2002; Koskela et al., 2003). Following 6–9 weeks 7/18 subjects had
no PD15. Following 6 months treatment 10/17 subjects had no PD15 and
the airway reactivity was within the non-asthmatic range, however four
subjects with a PD15 at 6 months had no PD15 at 3 months. AHR in
individuals on ICS who were once negative to mannitol can result
following a decrease in ICS dose (Leuppi et al., 2001) and suggest these
subjects may have decreased ICS adherence.
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(Jonasson et al., 2000; Brannan et al., 2002; Koskela et al., 2003;
Duong et al., 2008; Lipworth et al., 2012). There is also evidence of
an increase in AHR to indirect stimuli in individuals with estab-
lished asthma who have ICS withdrawn during down-titration of
ICS (Leuppi et al., 2001). Improvements in airway sensitivity to
mannitol with regular ICS occurs in association with the clin-
ical improvements expected with ICS over weeks to months of
treatment (Brannan et al., 2002; Koskela et al., 2003; Figure 5).
Clinical questionnaires such the Asthma Control Questionnaire
(Juniper et al., 1999b) and the Asthma Quality of Life Question-
naires (Juniper et al., 1999a) that have been validated to identify
clinical improvement after weeks of ICS therapy (Juniper et al.,
1994), show significant clinical improvements in AHR to manni-
tol following the introduction of ICS (Baraket et al., 2012; Turton
et al., 2012). There are also improvements in airway reactivity with
ICS which is documented as the response dose ratio (% final fall
in FEV1 divided by the dose of mannitol to cause that fall). This is
a useful outcome to document efficacy of regular treatment using
ICS that results in no significant reduction in FEV1 (i.e., <10 or
15%). The reactivity to mannitol can be reduced in asthmatics
following effective ICS therapy to levels similar to those observed
in non-asthmatic subjects (Brannan et al., 2012).
A recent study assessed the use of the mannitol challenge to
monitor progress to ICS by re-assessing AHR every 2 months for
a year following the introduction of ciclesonide. Those who had
AHR monitored had significant reductions in mild exacerbations
compared to those monitored using asthma guidelines (Lipworth
et al., 2012). Those who had their asthma monitored using inhaled
mannitol also had greater reductions in AHR to mannitol, metha-
choline, and FeNO levels compared to those monitored using
guidelines. This finding suggested greater improvement in both
AHR and airway inflammation with the AHR strategy. This was
observed in association with significant improvements the fre-
quency of night and day symptoms and decreased β2-agonist
use, which was not observed in those monitored using the refer-
ence strategy that used asthma guidelines. This study also showed
more ICS were used in subjects managed using an AHR strategy,
however this twofold increased dose of ciclesonide showed no
significant increase in urinary cortisol compared to the lower
doses in the reference strategy. Considering this outcome, AHR
to mannitol was mild but was still present over 12 months of ICS
treatment.
When using an indirect stimulus to monitor ICS, an end point
to identify optimal treatment is the documentation of no AHR to
these stimuli (Koskela et al., 2003; Brannan et al., 2007). In both
adults and children, it has been shown that a loss in responsiveness
to these stimuli is possible following weeks to months of the com-
mencement of ICS, with more rapid benefits (over 8–12 weeks)
observed in those with milder AHR (Jonasson et al., 2000; Brannan
et al., 2002). The loss of AHR to these stimuli suggests that there
has been a significant decrease in the cellular source of mediators
following regular ICS. The inhibition of indirect AHR in those
initially demonstrating airway sensitivity to these stimuli before
ICS, suggests a sufficient decrease in the presence and interac-
tion of the key features of asthma, airway inflammation and AHR.
Future studies need to address the longer-term clinical benefits
on outcomes such as exacerbations and asthma control in those
who achieve a loss of AHR to indirect stimuli following regular
ICS therapy. Such a strategy may assist in achieving the required
outcome of asthma guidelines that recommend control of asthma
using the minimum dose of ICS [Global Initiative for Asthma
(GINA), 2007].
CONCLUSION
Tests for AHR are useful objective measures to aid in asthma diag-
nosis by identifying a central feature of asthma. It is important
to understand the differences in mechanisms between direct and
indirect tests in order to employ them appropriately both in a
clinical and research environment. Both direct and indirect tests
for AHR have revealed much about the mechanisms of AHR in
asthma, as well as the mechanisms of action of pharmacotherapy
used to inhibit AHR. Future research should evaluate the features
of airway remodeling that may contribute to the airway response
as well as further evaluation of their role in monitoring asthma
therapy such as ICS in order to achieve and sustain asthma control
on minimal therapy.
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